Why is PT-141 approved but Melanotan II is not?

PT-141 and Melanotan II are structurally similar melanocortin analogues but sit at very different regulatory positions. Melanotan II was designed at the University of Arizona in the 1990s as a broad-spectrum α-MSH analogue with activity at MC1R, MC3R, MC4R, and MC5R. It was never developed into an approved drug — instead, its accidental observation of pro-erectogenic effects in male study participants reframed the entire melanocortin space and led Palatin Technologies to develop a structurally-refined variant.

PT-141 (bremelanotide) differs from Melanotan II in the C-terminal chemistry (amide vs free acid) which shifts receptor selectivity toward MC4R — the receptor most directly involved in the appetitive-sexual-desire pathway. Palatin took this refined molecule through a formal clinical development program targeting female hypoactive sexual desire disorder (HSDD). The subcutaneous 1.75 mg formulation completed phase 3 (RECONNECT trials, Kingsberg 2019 Obstetrics & Gynecology) and received FDA approval as Vyleesi in June 2019.

Melanotan II remained in the grey market throughout this process. It has multiple regulator warnings (UK MHRA in particular) about cosmetic-tanning use, and the specific concern about naevus (mole) changes during use has been documented in case reports (Cardones 2009). There is no completed clinical trial program for Melanotan II in any indication, and no regulatory sponsor has taken it forward. This is a case where two structurally similar molecules ended up in very different places — one because it was developed formally through the regulatory framework, one because it was not.